RE:Factfossi, "It is clear to everyone here - there will be an increase in capital." fossi misrepresents the company's stated word. The company will be "well-capitalized" according to the news release.
- "Strengthened combined balance sheet. The combined company will be well-capitalized to support ongoing commercial operations while strategically investing in product research and development to advance differentiated, innovative products."
AEZS's significant cash, plus CZO's cash plus potential upfront and milestone payments for AEZS's diagnostic test and from PGX as well as from other potential to be partnered programs of CZO and AEZS provide a significant cash runway. Royalty revenue from AEZS's diagnostic test and revenue from CZO's base business also support the company. Capital from AEZS will further be directed into near-term revenue generation programs in CZO's pipeline as indicated by the news release. The objective is to build a long-term sustainable business it is stated in the news release.